The FINANCIAL -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced 48-week data from the BRAAVE 2020 study, a Phase 3 clinical trial evaluating the safety and efficacy of switching to Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in virologically suppressed adults living with HIV who self-identified as Black or African American. These data ...

More Articles ...

More Articles ...

The FINANCIAL -- The Board of Directors of Bristol-Myers Squibb Company declared an increase of 2.5% percent in the company’s quarterly dividend, beginning in the first quarter of ...

The FINANCIAL -- Eli Lilly and Company and ARMO BioSciences, Inc. on May 10 announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash ...

The FINANCIAL -- The Bayer Group aims to significantly enhance its performance in the coming years and has set itself ambitious growth and margin targets through ...

The FINANCIAL -- Novel results based on data from the landmark EMPA-REG OUTCOME trial were published in the journal Circulation which suggest that treatment with Jardiance  positively impacts life ...

The FINANCIAL -- Bayer announced on May 11 that Eylea (aflibercept solution for injection into the eye) has been approved by the Chinese regulatory authorities for the treatment of visual impairment ...

THe FINANCIAL -- Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying ...

The FINANCIAL -- Insecure, illicit, infectious—three I’s no one wants near their eyes, which is why the AOA is issuing a Halloween warning against illegally sold contact lenses and urging doctors ...

The FINANCIAL -- Boehringer Ingelheim has developed ASF COMBAT (ASF Comprehensive Online Management and Biosecurity Assessment Tool). This tool enables pig producers to evaluate areas for biosecurity ...

Videos

Watch the video